Stem Cell Therapy Offers New Hope for Parkinson’s Disease
A groundbreaking clinical trial is underway, offering a potential new avenue for treating Parkinson’s disease by restoring the brain’s ability to produce dopamine. This innovative approach involves implanting lab-grown stem cells directly into the brain, aiming to alleviate symptoms and potentially leisurely the disease’s progression.
Understanding Parkinson’s Disease and Dopamine
Parkinson’s disease is a progressive neurological disorder affecting more than 1.1 million people in the United States, with approximately 90,000 new cases diagnosed annually [1]. The condition is characterized by the gradual loss of dopamine-producing neurons in the brain, leading to motor symptoms like tremors, muscle stiffness, and slowed movement [2]. Dopamine is a crucial chemical messenger responsible for controlling movement, mood, memory, and other essential functions [2].
Currently available medications and therapies can manage symptoms, but no treatment has been proven to halt or reverse the disease itself [1]. As dopamine-producing cells die, the brain’s ability to regulate movement is compromised, resulting in the hallmark symptoms of Parkinson’s [1].
The Stem Cell Therapy Approach
Researchers at Keck Medicine of USC are pioneering a new treatment strategy focused on directly addressing dopamine loss. The clinical trial involves implanting specially engineered stem cells into the brain to replace the damaged neurons and restore dopamine production [1].
The treatment utilizes induced pluripotent stem cells (iPSCs), a newer type of lab-created stem cell. IPSCs are generated by reprogramming adult cells (like those from skin or blood) into a versatile state, allowing them to develop into various cell types within the body [1]. “We believe that these iPSCs can reliably mature into dopamine-producing brain cells, and offer the best chance of jump-starting the brain’s dopamine production,” said Xenos Mason, MD, a neurologist with Keck Medicine [1].
The Procedure and Monitoring
During the procedure, a neurosurgeon creates a little opening in the skull to access the brain. Using magnetic resonance imaging (MRI) for guidance, the stem cells are carefully placed into the basal ganglia, the brain region responsible for coordinating movement [1].
Following the operation, participants are closely monitored for 12-15 months to assess changes in symptoms and identify any potential side effects, such as dyskinesia (excess movements) or infection [1]. Researchers plan to continue monitoring patients for up to five years.
Clinical Trial Details and Speedy-Track Designation
Keck Medicine is one of three sites in the United States participating in the clinical trial, which involves 12 individuals with moderate to moderate-severe Parkinson’s disease [1]. The stem cell therapy, known as RNDP-001, is developed by Kenai Therapeutics, a biotechnology company specializing in neurological disorder treatments [1].
The U.S. Food & Drug Administration (FDA) has granted the clinical trial, Phase 1 REPLACE™, fast-track designation to expedite the development and review process [1].
Looking Ahead
“Our ultimate goal is to pioneer a technique that can repair patients’ motor function and offer them a better quality of life,” said Brian Lee, MD, PhD, a neurosurgeon with Keck Medicine [1]. This clinical trial represents a significant step forward in the search for effective treatments for Parkinson’s disease, offering hope for improved outcomes for those living with this challenging condition.